Complexation of albendazole with hydroxypropyl-β-cyclodextrin significantly improves its pharmacokinetic profile, cell cytotoxicity and antitumor efficacy in nude mice

Anticancer Research

Volumn 32, Issue 9, 2012, Pages 3659-3666

  Ehteda, Anahid ^a   Galettis, Peter ^b   Chu, Stephanie Ling Wai ^a   Pillai, Krishna ^a   Morris, David L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

Acetic acid; Albendazole; Complexation; Hydroxypropyl cyclodextrin; Ionization; Pharmacokinetics

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACETIC ACID; ALBENDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SURVIVAL TIME; TUMOR GROWTH;

ACETIC ACID; ALBENDAZOLE; ANIMALS; BETA-CYCLODEXTRINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAPERITONEAL; METHYLCELLULOSE; MICE; MICE, NUDE; SOLUTIONS; SUSPENSIONS; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867000700     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Evrard B, Chiap P, DeTullio P, Ghalmi F, Piel G, Van Hees T, Crommen J, Losson B and Delattre L: Oral bioavailability in sheep of albendazole from a suspension and from a solution containing hydroxypropyl-beta-cyclodextrin. J Control Release 85: 45-50, 2002. (Pubitemid 35449452)
2. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P and Morris DL: In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 165: 43-49, 2001. (Pubitemid 32206656)
3. Pourgholami MH, Akhter J, Wang L, Lu Y and Morris DL: Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis. Cancer Chemother Pharmacol 55: 425-432, 2005. (Pubitemid 40568971)
4. Pourgholami MH, Yan Cai Z, Lu Y, Wang L and Morris DL: Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 12: 1928-1935, 2006.
5. Bassani VL, Krieger D, Duchene D and Wouessidjewe D: Enhanced water-solubility of albendazole by hydroxypropyl-β-cyclodextrin complexation. Journal of Inclusion Phenomena and Macrocyclic Chemistry 25: 149-152, 1996. (Pubitemid 126648442)
6. Marriner SE, Morris DL, Dickson B and Bogan JA: Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 30: 705-708, 1986. (Pubitemid 16018950)
7. Mingjie W, Shuhua X, Junjie C, Bin L, Cheng F, Weixia S and Hotez P: Albendazole-soybean oil emulsion for the treatment of human cystic echinococcosis: evaluation of bioavailability and bioequivalence. Acta Trop 83: 177-181, 2002. (Pubitemid 34671165)
8. Redondo PA, Alvarez AI, García JL, Villaverde C and Prieto JG: Influence of surfactants on oral bioavailability of albendazole based on the formation of the sulphoxide metabolites in rats. Biopharm Drug Dispos 19: 65-70, 1998. (Pubitemid 28064492)
9. Wen H, New RR, Muhmut M, Wang JH, Wang YH, Zhang JH, Shao YM and Craig PS: Pharmacology and efficacy of liposome-entrapped albendazole in experimental secondary alveolar echinococcosis and effect of co-administration with cimetidine. Parasitology 113: 111-121, 1996. (Pubitemid 26337057)
10. Palomares-Alonso F, González CR, Bernad-Bernad MJ, Montiel MD, Hernández GP, González-Hernández I, Castro-Torres N, Estrada EP and Jung-Cook H: Two novel ternary albendazole-cyclodextrin- polymer systems: dissolution, bioavailability and efficacy against Taenia crassiceps cysts. Acta Trop 113: 56-60, 2010.
11. Torrado S, Torrado S, Torrado JJ and Cadórniga R: Preparation, dissolution and characterization of albendazole solid dispersions. Int J Pharm 140: 247-250, 1996. (Pubitemid 26292771)
12. Ceballos L, Elissondo C, Moreno L, Dopchiz M, Sánchez Bruni S, Denegri G, Alvarez L and Lanusse C: Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations. Parasitol Res 103: 355-362, 2008.
13. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce- Gordo F and Torrado JJ: Effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 272: 29-36, 2004. (Pubitemid 38293008)
14. Torrado S, Cadorniga R and Torrado JJ: Formulation parameters of albendazole solution. Int J Pharm 140: 45-50, 1996. (Pubitemid 26276713)
15. Casulli A, Morales MA, Gallinella B, Turchetto L and Pozio E: 2-Hydroxypropyl-beta-cyclodextrin improves the effectiveness of albendazole against encapsulated larvae of Trichinella spiralis in a murine model. J Antimicrob Chemother 58: 886-890, 2006. (Pubitemid 44390973)
16. García JJ, Bolás F and Torrado JJ: Bioavailability and efficacy characteristics of two different oral liquid formulations of albendazole. Int J Pharm 250: 351-358, 2003. (Pubitemid 36084359)
17. Rigter IM, Schipper HG, Koopmans RP, van Kan HJ, Frijlink HW, Kager PA and Guchelaar HJ: Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Antimicrob Agents Chemother 48: 1051-1054, 2004. (Pubitemid 38280368)
18. Kalaiselvan R, Mohanta GP, Madhusudan S, Manna PK and Manavalan R: Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Pharmazie 62: 604-607, 2007. (Pubitemid 47326167)
19. Jung H, Medina L, García L, Fuentes I and Moreno-Esparza R: Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J Pharm Pharmacol 50: 43-48, 1998. (Pubitemid 28052519)
20. Strickley RG: Solubilizing excipients in oral and injectable formulations. Pharm Res 21: 201-230, 2004.
21. Challa R, Ahuja A, Ali J and Khar RK: Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 6: E329-357, 2005.
22. Rasheed A, Kumar CKA and Sravanthi VVNSS: Cyclodextrins as Drug Carrier Molecule: A Review. Sci Pharm 76: 567-598, 2008.
23. Uekama K and Otagiri M: Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst 3: 1-40, 1987. (Pubitemid 17231927)
24. Gould S and Scott RC: 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol 43: 1451-1459, 2005.
25. Pourgholami MH, Wangoo KT and Morris DL: Albendazolecyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. Anticancer Res 28: 2775-2779, 2008.
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990. (Pubitemid 20213250)
27. Dvorak HF, Nagy JA, Dvorak JT and Dvorak AM: Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95-109, 1988.
28. Frijlink HW, Franssen EJ, Eissens AC, Oosting R, Lerk CF and Meijer DK: The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm Res 8: 380-384, 1991.
29. Sideris EE, Koupparis MA, and Macheras PE: Effect of cyclodextrins on protein binding of drugs: the diflunisal/ hydroxypropyl-beta-cyclodextrin model case. Pharm Res 11: 90-95, 1994. (Pubitemid 24040769)
30. Díaz D, Bernad Bernad MJ, Gracia Mora J and Escobar Llanos CM: Complexation and solubility behavior of albendazole with some cyclodextrins. Pharm Dev Technol 3: 395-403, 1998. (Pubitemid 28410367)